Zhang Haiwei, Zhou Hongxia, Xia Xugang, Cao Qilin, Liu Ying
Center for Translational Science, Florida International University, 11350 SW Village Pkwy, Port St. Lucie, FL 34987, USA.
Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL 33199, USA.
Cells. 2025 Aug 13;14(16):1248. doi: 10.3390/cells14161248.
Human induced pluripotent stem cells (iPSCs) can be genetically engineered to evade host immune recognition, rendering them hypoimmunogenic and suitable as "universal donor" cells for allogeneic transplantation. Such modifications enable the development of off-the-shelf iPSC-derived therapeutics that are immediately available for clinical use without the need for patient-specific derivation or immunosuppression. This review focuses on recent developments in strategies for generating hypoimmunogenic human iPSCs, with particular emphasis on their applications in central nervous system (CNS) cell therapy and repair. We assess immunomodulatory factors based on their immune functions and potential roles in CNS development and disease, with the goal of identifying strategies to use these factors either individually, in combination, or alongside gene editing to reduce immune rejection without compromising neurogenesis or tissue repair.
人类诱导多能干细胞（iPSC）可通过基因工程改造以逃避宿主免疫识别，使其免疫原性降低，适合作为异基因移植的“通用供体”细胞。此类修饰能够开发出现成的iPSC衍生疗法，无需针对患者进行特定诱导或免疫抑制即可立即用于临床。本综述重点关注产生低免疫原性人类iPSC策略的最新进展，尤其强调其在中枢神经系统（CNS）细胞治疗和修复中的应用。我们根据免疫调节因子的免疫功能及其在CNS发育和疾病中的潜在作用进行评估，目的是确定单独使用、联合使用这些因子或与基因编辑一起使用的策略，以减少免疫排斥，同时不损害神经发生或组织修复。
